Sanford Research, a non-profit research organization based in Sioux Falls, South Dakota, was awarded a $194,013 Project Grant (R21CA286286) from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant funds the development and characterization of genetically engineered mouse models that replicate key features of human high-risk rhabdomyosarcoma, a prevalent soft tissue sarcoma in children. The research aims to elucidate the role of the Notch1 signaling pathway in rhabdomyosarcoma progression and evaluate Notch inhibition as a targeted therapeutic approach. By integrating advanced molecular analyses with robust in vivo models, the project seeks to improve understanding of Notch-driven rhabdomyosarcoma and identify transformative cancer treatments. The research award period runs from December 11, 2024 to November 30, 2026.
Generated 1/28/25, 10:57 AM